Company research
Boundless Bio, Inc.
CIK 1782303Updated Sep 24, 2026
SecurityBOLD · NASDAQ · equity
BOLD price & chart
Loading TradingView…
NASDAQ:BOLD on TradingView ↗About the company
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. For more information, visit https://boundlessbio.com/.
In the news
These Emerging Companies Are Racing Toward Major Catalysts ↗
These Emerging Companies Are Racing Toward Major Catalysts ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 157,059,000Source | 206,409,000Source | 129,894,000Source |
| Property, Plant and Equipment, NetUSD | 3,216,000Source | 4,321,000Source | 2,573,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 17,868,000Source | 26,587,000Source | 23,706,000Source |
| Assets, CurrentUSD | 109,611,000Source | 154,390,000Source | 124,204,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,030,000Source | 2,276,000Source | 3,452,000Source |
| Operating Lease, Right-of-Use AssetUSD | 43,659,000Source | 47,039,000Source | 2,002,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 58,405,000Source | 55,767,000Source | 9,359,000Source |
| Stockholders’ equity: | |||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,000Source | 2,000Source | 0Source |
| Additional Paid in CapitalUSD | 358,257,000Source | 351,991,000Source | 8,987,000Source |
| Retained Earnings (Accumulated Deficit)USD | -259,669,000Source | -201,472,000Source | -136,109,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 64,000Source | 121,000Source | 40,000Source |
| Stockholders' Equity Attributable to ParentUSD | 98,654,000Source | 150,642,000Source | -127,082,000Source |
| Liabilities and EquityUSD | 157,059,000Source | 206,409,000Source | 129,894,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 12,537,000Source | 8,135,000Source | 9,359,000Source |
| Operating Lease, Liability, CurrentUSD | 3,167,000Source | — | 2,195,000Source |
| Accounts Payable, CurrentUSD | 1,491,000Source | 1,274,000Source | 2,222,000Source |
| Operating Lease, Liability, NoncurrentUSD | 45,868,000Source | 47,632,000Source | — |
| Additional Financial Items | |||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 107,600,000Source | 152,100,000Source | — |
| Short-term InvestmentsUSD | 89,713,000Source | 125,527,000Source | 97,046,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -58,197,000Source | -65,363,000Source | -49,434,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 1,251,000Source | 1,086,000Source | 957,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,125,000Source | 7,516,000Source | 3,336,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -46,661,000Source | -60,841,000Source | -46,855,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 37,801,000Source | -26,101,000Source | -38,260,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 546,000Source | 2,536,000Source | 633,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 141,000Source | 89,823,000Source | 97,897,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -8,719,000Source | 2,881,000Source | 12,782,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 18,428,000Source | 27,147,000Source | 24,266,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 6,125,000Source | 7,516,000Source | 3,336,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 107,600,000Source | 152,100,000Source | — |
| General and Administrative ExpenseUSD | 18,707,000Source | 18,000,000Source | 12,159,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Investment Income, InterestUSD | 5,357,000Source | 7,892,000Source | 5,282,000Source |
| Net Income (Loss) Attributable to ParentUSD | -58,197,000Source | -65,363,000Source | -49,434,000Source |
| Nonoperating Income (Expense)USD | 5,355,000Source | 7,904,000Source | 5,362,000Source |
| Operating ExpensesUSD | 63,552,000Source | 73,267,000Source | 54,796,000Source |
| Other Nonoperating Income (Expense)USD | -2,000Source | 12,000Source | 80,000Source |
| Payments to Acquire InvestmentsUSD | 174,897,000Source | 208,465,000Source | 160,123,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 62,000Source | 182,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -63,552,000Source | -73,267,000Source | -54,796,000Source |
| Other Nonoperating Income (Expense)USD | -2,000Source | 12,000Source | 80,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -58,197,000Source | -65,363,000Source | -49,434,000Source |
| Earnings Per Share, BasicUSD per share | -2.6Source | -3.85Source | -40.65Source |
| Earnings Per Share, DilutedUSD per share | -2.6Source | -3.85Source | -40.65Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 22,360,000Source | 16,984,000Source | 1,216,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 22,360,000Source | 16,984,000Source | 1,216,000Source |
| Additional Financial Items | |||
| Current Income Tax Expense (Benefit)USD | 0Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,300,000Source | 1,100,000Source | 1,000,000Source |
| General and Administrative ExpenseUSD | 18,707,000Source | 18,000,000Source | 12,159,000Source |
| Investment Income, InterestUSD | 5,357,000Source | 7,892,000Source | 5,282,000Source |
| Nonoperating Income (Expense)USD | 5,355,000Source | 7,904,000Source | 5,362,000Source |
| Operating ExpensesUSD | 63,552,000Source | 73,267,000Source | 54,796,000Source |
| Research and Development ExpenseUSD | 44,845,000Source | 55,267,000Source | 42,637,000Source |
Filing attachments
d159021dex991.htm · 8-K · 2026-06-23
EX-99.1 7 d159021dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement Combined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K (PiZZ) mutation, with proof-of-concept data demonstrating restoration of serum AAT to normal levels Concurrent $230 mi…
Read attachment ↗d159021dex992.htm · 8-K · 2026-06-23
EX-99.2 8 d159021dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Boundless Bio & Serapha BioConference Call Script Operator Good morning and welcome to the Boundless Bio conference call to discuss the merger of Boundless and Serapha Bio. This call is being recorded for replay at the company’s request. It’s now my pleasure to turn the call over to Monique Allaire, IR representative for Boundless Bio. Please go ahead. Monique Allaire Good morning and thank you for joining us for today’s conferen…
Read attachment ↗bold-ex99_1.htm · 8-K · 2026-05-08
EX-99.1 2 bold-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 8, 2026 - Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies …
Read attachment ↗